Serum C-reactive protein and congestive heart failure as significant predictors of herpes zoster vaccine response in elderly nursing home residents

Journal of Infectious Diseases

Volumn 216, Issue 2, 2017, Pages 191-197

  Verschoor, Chris P ^a,b,c   Lelic, Alina ^a   Parsons, Robin ^a   Evelegh, Carole ^a   Bramson, Jonathan L ^a   Johnstone, Jennie ^d   Loeb, Mark B ^a   Bowdish, Dawn M E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Étude longitudinale canadienne sur le vieillissement éLCV   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Heart failure; Immunosenescence; Inflammation; Vaccination; Varicella zoster

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; VARICELLA ZOSTER VACCINE; CYTOKINE;

AGED; ARTICLE; CANADA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CHRONIC LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DRUG RESPONSE; DRUG TREATMENT FAILURE; EFFECTOR CELL; FEMALE; FRAILTY; HEMIPLEGIA; HUMAN; HUMAN CELL; IMMUNOSENESCENCE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PERIPHERAL VASCULAR DISEASE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TELOMERE LENGTH; VERY ELDERLY; BLOOD; CELLULAR IMMUNITY; HEART FAILURE; HERPES ZOSTER; HOME FOR THE AGED; IMMUNOLOGY; LONG TERM CARE; MIDDLE AGED; NURSING HOME; STATISTICAL MODEL; T LYMPHOCYTE; TELOMERE; ULTRASTRUCTURE; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CANADA; CYTOKINES; FEMALE; HEART FAILURE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HOMES FOR THE AGED; HUMANS; IMMUNITY, CELLULAR; IMMUNOSENESCENCE; LINEAR MODELS; LOGISTIC MODELS; LONG-TERM CARE; MALE; MIDDLE AGED; NURSING HOMES; T-LYMPHOCYTES; TELOMERE;

EID: 85028383594     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix257     Document Type: Article

References (47)

1. Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the antelope valley varicella active surveillance project data. Vaccine 2013; 31:1680-94.
2. O'Connor KM, Paauw DS. Herpes zoster. Med Clin North Am 2013; 97:503-22, ix.
3. Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A. Update on herpes zoster vaccination: A family practitioner's guide. Can Fam Physician 2011; 57:1127-31.
4. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56.
5. Levin MJ, Oxman MN, Zhang JH, et al; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35.
6. Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 2016; 213:14-22.
7. Irwin MR, Levin MJ, Carrillo C, et al. Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun 2011; 25:759-66.
8. Alicino C, Trucchi C, Paganino C, et al. Incidence of herpes zoster and post-herpetic neuralgia in Italy: results from a 3-years population-based study. Hum Vaccin Immunother 2017; 13:399-404.
9. Drinka PJ. How should nursing homes use vaccine to prevent zoster? J Am Med Dir Assoc 2007; 8:419-20.
10. Lelic A, Verschoor CP, Lau VW, et al. Immunogenicity of varicella vaccine and immunologic predictors of response in a cohort of elderly nursing home residents. J Infect Dis 2016; 214:1905-10.
11. Xing Q, Hu D, Shi F, Chen F. Role of regulatory T cells in patients with acute herpes zoster and relationship to postherpetic neuralgia. Arch Dermatol Res 2013; 305:715-22.
12. Clement M, Marsden M, Stacey MA, et al. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. PLoS Pathog 2016; 12:e1006050.
13. Hata A, Inoue F, Yamasaki M, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. J Infect 2013; 67:215-9.
14. Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis 2013; 56:1085-93.
15. Qi Q, Cavanagh MM, Le Saux S, et al. Defective T memory cell differentiation after varicella zoster vaccination in older individuals. PLoS Pathog 2016; 12:e1005892.
16. Rockwood K, Mogilner A, Mitnitski A. Changes with age in the distribution of a frailty index. Mech Ageing Dev 2004; 125:517-9.
17. Disis ML, dela Rosa C, Goodell V, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 2006; 308:13-8.
18. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009; 37:e21.
19. Johnstone J, Parsons R, Botelho F, et al. T-cell phenotypes predictive of frailty and mortality in elderly nursing home residents. J Am Geriatr Soc 2017; 65:153-9.
20. Johnstone J, Parsons R, Botelho F, et al. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PLoS One 2014; 9:e108481.
21. Johnstone J, Millar J, Lelic A, et al. Immunosenescence in the nursing home elderly. BMC Geriatr 2014; 14:50.
22. McElhaney JE, Kuchel GA, Zhou X, Swain SL, Haynes L. T-cell immunity to influenza in older adults: A pathophysiological framework for development of more effective vaccines. Front Immunol 2016; 7:41.
23. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006; 24:1159-69.
24. Sato M, Saito R, Tanabe N, et al. Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan. Infect Control Hosp Epidemiol 2005; 26:859-66.
25. Iorio AM, Alatri A, Camilloni B, Neri M, Baglio G, Donatelli I. Antibody response to 1995-1996 influenza vaccine in institutionalized and non-institutionalized elderly women. Gerontology 1999; 45:31-8.
26. Muszkat M, Friedman G, Dannenberg HD, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol 2003; 38:1199-203.
27. Sagawa M, Kojimahara N, Otsuka N, Kimura M, Yamaguchi N. Immune response to influenza vaccine in the elderly: association with nutritional and physical status. Geriatr Gerontol Int 2011; 11:63-8.
28. Miyagawa K, Hayashi Y, Kurihara S, Maeda A. Co-administration of l-cystine and l-theanine enhances efficacy of influenza vaccination in elderly persons: nutritional status-dependent immunogenicity. Geriatr Gerontol Int 2008; 8:243-50.
29. Bellei NC, Carraro E, Castelo A, Granato CF. Risk factors for poor immune response to influenza vaccination in elderly people. Braz J Infect Dis 2006; 10:269-73.
30. Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: A randomized placebo-controlled trial. J Med Virol 2009; 81:908-14.
31. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6:268ra179.
32. Langkamp-Henken B, Wood SM, Herlinger-Garcia KA, et al. Nutritional formula improved immune profiles of seniors living in nursing homes. J Am Geriatr Soc 2006; 54:1861-70.
33. Woods JA, Keylock KT, Lowder T, et al. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: The immune function intervention trial. J Am Geriatr Soc 2009; 57:2183-91.
34. Alter G, Sekaly RP. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine 2015; 33(suppl 2):B55-9.
35. Bukhari SSI, Phillips BE, Wilkinson DJ, et al. Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. Am J Physiol Endocrinol Metab 2015; 308:E1056-65.
36. Furman D, Jojic V, Kidd B, et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013; 9:659.
37. Naylor C, Lu M, Haque R, et al; PROVIDE study teams. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine 2015; 2:1759-66.
38. Baeyens A, Saadoun D, Billiard F, et al. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context. J Immunol 2015; 194:999-1010.
39. Wang CS, Wang ST, Lai CT, Lin LJ, Lee CT, Chou P. Reducing major cause-specific hospitalization rates and shortening hospital stays after influenza vaccination. Clin Infect Dis 2004; 39:1604-10.
40. Seo YB, Choi WS, Baek JH, et al. Effectiveness of the influenza vaccine at preventing hospitalization due to acute exacerbation of cardiopulmonary disease in Korea from 2011 to 2012. Hum Vaccin Immunother 2014; 10:423-27.
41. Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 2014; 16:264-70.
42. Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ. Can vaccinations improve heart failure outcomes? contemporary data and future directions. JACC Heart Fail 2017; 5:194-203.
43. Vardeny O, Sweitzer NK, Detry MA, Moran JM, Johnson MR, Hayney MS. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 2009; 15:368-73.
44. Albrecht CM, Sweitzer NK, Johnson MR, Vardeny O. Lack of persistence of influenza vaccine antibody titers in patients with heart failure. J Card Fail 2014; 20:105-9.
45. McElhaney JE, Herre JM, Lawson ML, Cole SK, Burke BL, Hooton JW. Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults. Vaccine 2004; 22:681-8.
46. Bansal SS, Ismahil MA, Goel M, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail 2017; 10:e003688.
47. Xydonas S, Parissis J, Lioni L, et al. Immunosenescence in patients with chronic systolic heart failure. J Cardiovasc Med 2016; 17:624-30.